News

How Ozempic’s Maker Lost Its Shine After Creating a Wonder Drug

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Covington Ramps Up Novo Nordisk's Legal Blitz For Ozempic Trademark Cases

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...
Investor's Business Daily on MSN2d

Novo Nordisk Slumps As 'Unlawful' Knockoffs Pressure Wegovy, Ozempic

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

Novo Nordisk: This Won't Last

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
24/7 Wall St.10d

Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo Nordisk expands lawsuits against weight-loss drug compounders

Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...

Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Ozempic maker Novo Nordisk has its worst day since Black Monday

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Futurism on MSN1d

The Creator of Ozempic Is in Terrible Trouble

Novo Nordisk's flagship product is semaglutide. Sold under the names Ozempic and Wegovy, it's one of the leading GLP-1 ...